Background: Prostate specific antigen (PSA) and PSA velocity (PSAV, rate of PSA change over time) are biomarkers for diagnosis and prognosis of prostate cancer (PCa).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Men who are at high risk for PCa also have associated co-morbidities for which they are taking NSAIDs and statins for long periods; therefore it is important to understand the effect of these medications on markers used to assess PCa risk.
Methods: Using a population of 699 men, multiple linear regressions were used to investigate the associations between PSA and concomitant medications; and mixed effects models were used to investigate these associations with PSAV.
Results: After adjusting for selenium use, age, race, body mass index, and pack-years of smoking; aspirin, other NSAIDs, or statins did not demonstrate statistically significant associations with PSA (p = 0.79, 0.68, and 0.79 respectively) or PSAV (p = 0.23, 0.43, and 0.84 respectively). Results were not altered upon stratifying the sample between men who developed PCa during the course of the study and those who did not.
Conclusions: Results from this study indicate that chronic use of aspirin, other NSAIDs, or statins did not impact PSA levels or PSAV in men at high risk for PCa. Larger prospective studies designed to investigate these relationships are needed to confirm this result.
Impact: Long-term use of NSAIDs or statins in men at high risk for PCa may not interfere with the diagnosis or prognosis of this disease, and supports appropriate use of these medications with regard to PCa risk.
Algotar AM, Behnejad R, Stratton MS, Stratton SP. Are you the author?
Arizona Cancer Center, University of Arizona.
Reference: Cancer Epidemiol Biomarkers Prev. 2014 Jul 24. pii: cebp.0605.2014.